{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:50:04Z","timestamp":1785876604152,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009068","name":"University of Bern","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014867","name":"Department for BioMedical Research, Universit\u00e4t Bern","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["TMSGI3_225913"],"award-info":[{"award-number":["TMSGI3_225913"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218691","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:32:00Z","timestamp":1782257520000},"page":"218691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models"],"prefix":"10.1016","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5197-0381","authenticated-orcid":false,"given":"Caroline","family":"Piccand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-5551","authenticated-orcid":false,"given":"Corentin","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2381-0908","authenticated-orcid":false,"given":"Pascal","family":"Kl\u00f6ckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3101-3114","authenticated-orcid":false,"given":"Sara G.","family":"Danielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vokuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Haesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-9551","authenticated-orcid":false,"given":"Andreina","family":"Schoeberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Br\u00fcningk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-8343","authenticated-orcid":false,"given":"Rhoikos","family":"Furtw\u00e4ngler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-3481","authenticated-orcid":false,"given":"Andrea","family":"Timpanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-8806","authenticated-orcid":false,"given":"Michele","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218691_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2026.218691_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218691_bib3","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2009.26.3814","article-title":"Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma","volume":"28","author":"Williamson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib4","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1002\/cam4.2504","article-title":"Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the children's oncology group","volume":"8","author":"Hibbitts","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218691_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70215","article-title":"Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the cooperative Weichteilsarkom Studiengruppe CWS","volume":"14","author":"Koscielniak","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218691_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26386","article-title":"Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: retrospective analyses of patients on UK trials","volume":"64","author":"Selfe","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31436","article-title":"Implications of Implementing children's oncology group risk stratification to patients with rhabdomyosarcoma treated on European paediatric soft tissue sarcoma study group clinical trial","volume":"72","author":"Bisogno","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218691_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib10","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218691_bib11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/1535-7163.MCT-22-0059","article-title":"FGFR4-Targeted chimeric antigen receptors combined with anti-myeloid polypharmacy effectively treat orthotopic rhabdomyosarcoma","volume":"21","author":"Sullivan","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218691_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","article-title":"CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models","volume":"42","author":"Timpanaro","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib13","article-title":"Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma","volume":"4","author":"Tian","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218691_bib14","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","article-title":"CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma","volume":"15","author":"Tian","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218691_bib15","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib16","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032601","article-title":"Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma","volume":"24","author":"Timpanaro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218691_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4161\/cam.20832","article-title":"L1CAM: a major driver for tumor cell invasion and motility","volume":"6","author":"Kiefel","year":"2012","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.canlet.2026.218691_bib20","doi-asserted-by":"crossref","first-page":"55276","DOI":"10.18632\/oncotarget.10527","article-title":"Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: an immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors","volume":"7","author":"Inaguma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218691_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2340\/1651-226X.2025.43587","article-title":"L1CAM\/CD171 expression in human tumors and its association with tumor phenotype","volume":"64","author":"Buyucek","year":"2025","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","article-title":"Preclinical assessment of CD171-Directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility","volume":"23","author":"Kunkele","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13046-021-02117-z","article-title":"L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1\/SRC\/STAT3 signaling","volume":"40","author":"Giordano","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","article-title":"CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing","volume":"19","author":"Andersch","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192525","article-title":"Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy","volume":"13","author":"Ernst","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218691_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","article-title":"Functional tuning of CARs reveals signaling threshold above which CD8+ CTL Antitumor potency is attenuated due to cell fas-fasl-dependent AICD","volume":"3","author":"Kunkele","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218691_bib27","article-title":"L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice","volume":"11","author":"Hong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218691_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0009","article-title":"The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma","author":"Pinto","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218691_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218691_bib32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218691_bib33","doi-asserted-by":"crossref","first-page":"339ra370","DOI":"10.1126\/scitranslmed.aad2986","article-title":"Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL","volume":"8","author":"McComb","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218691_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<401::AID-IJC17>3.0.CO;2-A","article-title":"Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells","volume":"83","author":"Meli","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade9238","article-title":"Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance","volume":"9","author":"Danielli","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218691_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218691_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s43856-022-00186-5","article-title":"TIAToolbox as an end-to-end library for advanced tissue image analytics","volume":"2","author":"Pocock","year":"2022","journal-title":"Commun. Med."},{"key":"10.1016\/j.canlet.2026.218691_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/hyb.1991.10.481","article-title":"The 200\/220 kDa antigen recognized by monoclonal antibody (MAb) UJ127.11 on neural tissues and tumors is the human L1 adhesion molecule","volume":"10","author":"Patel","year":"1991","journal-title":"Hybridoma"},{"key":"10.1016\/j.canlet.2026.218691_bib39","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/0008-5472.CAN-05-1818","article-title":"Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment","volume":"66","author":"Arlt","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218691_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ccell.2017.05.007","article-title":"A systems biology approach identifies FUT8 as a driver of Melanoma metastasis","volume":"31","author":"Agrawal","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218691_bib41","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0959-8049(02)00105-3","article-title":"Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma","volume":"38","author":"Thies","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib42","first-page":"909","article-title":"Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma","volume":"24","author":"Bergmann","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218691_bib43","doi-asserted-by":"crossref","DOI":"10.24450\/journals\/abrep.2025.e2341","article-title":"AN179 antibody recognizes specifically L1CAM by flow cytometry on rhabdomyosarcoma cell lines","volume":"8","author":"Piccand","year":"2025","journal-title":"Antibody Reports"},{"key":"10.1016\/j.canlet.2026.218691_bib44","article-title":"CAR T cells redirected to B7-H3 for pediatric solid tumors: current status and future perspectives","volume":"3","author":"Epperly","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CJI.0000000000000018","article-title":"Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes","volume":"37","author":"Hong","year":"2014","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2026.218691_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218691_bib47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/2326-6066.CIR-24-1347","article-title":"CAR binders affect CAR T-cell tonic signaling, durability, and sensitivity to target","volume":"13","author":"Shukla","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218691_bib48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(03)14342-5","article-title":"L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas","volume":"362","author":"Fogel","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218691_bib49","first-page":"257","article-title":"Binding of the transcription factor slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells","volume":"38","author":"Geismann","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2026.218691_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1476-4598-10-127","article-title":"L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer","volume":"10","author":"Tischler","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218691_bib51","series-title":"First-In-Human Comparison of second- Versus third-generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma (Available at Research Square","author":"Navin Pinto","year":"2024"},{"key":"10.1016\/j.canlet.2026.218691_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and t(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218691_bib53","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218691_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051050","article-title":"CD28 Co-Stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB Co-Stimulus","volume":"13","author":"Textor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218691_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315925121","article-title":"CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway","volume":"121","author":"Hernandez","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218691_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12920-017-0308-8","article-title":"Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types","volume":"10","author":"Budczies","year":"2017","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.canlet.2026.218691_bib57","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218691_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00404-016-4226-3","article-title":"The sL1CAM in sera of patients with endometrial and ovarian cancers","volume":"295","author":"Wojciechowski","year":"2017","journal-title":"Arch. Gynecol. Obstet."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:21:53Z","timestamp":1785874913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0304383526004556"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218691","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218691"}}